ANTWERP, Belgium–(BUSINESS WIRE)–REGULATED INFORMATION In accordance with Article 14 of the Belgian Transparency law of 2 May 2007, Azelis Group NV (Brussels:AZE) announces that on 15 September 2026 and 17 September 2026, it has received two transparency notifications from UBS Group AG. 1. Summary of the notifications UBS Group AG reported in its notification dated 15 September 2026, that on 11 September 2026, following an acquisition of equivalent financial instruments, UBS Group AG (taking

ANTWERPEN, België–(BUSINESS WIRE)–GEREGULEERDE INFORMATIE In overeenstemming met artikel 14 van de Belgische Transparantiewet van 2 mei 2007 maakt Azelis Group NV (Brussels:AZE) bekend dat het twee transparantiekennisgevingen heeft ontvangen van UBS Group AG op 15 september 2026 en 17 september 2026. 1. Samenvatting van de kennisgevingen UBS Group AG heeft in een kennisgeving gedateerd op 15 september 2026 gemeld dat op 11 september 2026, na een verwerving van gelijkgestelde financiële instru

PARIS–(BUSINESS WIRE)–Regulatory News: ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, announces that its wholly-owned US subsidiary has reached a settlement resolving an existing dispute, pursuant to which it will receive a payment of USD 2 million. The related proceedings have been dismissed. About ALIKO SCIENTIFIC Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an internation

PARIS–(BUSINESS WIRE)–Regulatory News: ALIKO Scientific (Ikonisys SA – Euronext Growth Paris : ALIKO), groupe international des sciences de la vie dédié au diagnostic oncologique intégré, annonce que sa filiale américaine détenue à 100 % a conclu un accord transactionnel mettant fin à un litige en cours, aux termes duquel elle percevra la somme de 2 millions de dollars américains. Les procédures judiciaires relatives à ce litige ont été closes. À propos d’ALIKO SCIENTIFIC (Ikonisys SA) Basée

LIESTAL, Switzerland–(BUSINESS WIRE)–Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturin

SANTA CLARA, Calif.–(BUSINESS WIRE)—- $MRVL #2nm–Marvell Technology, Inc. (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, today announced industry-first 2nm optical interconnect demonstrations that advance the next generation of AI data center connectivity. The technologies will be showcased at the European Conference on Optical Communication (ECOC) 2026, September 20–24, 2026, in Málaga, Spain, underscoring how Marvell continually delivers new waves of advanced connectivity solut

ZUG, Switzerland–(BUSINESS WIRE)–Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland’s leading blue chip equity benchmark comprising 20 of the country’s largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland’s leading listed companies. Its inclusion in the SMI reflects the company’s

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.